Quince’s discovery pipeline is positioned for rapid expansion across multiple skeletal therapeutic indications, including osteogenesis imperfecta, fractures, spinal fusion, and other severe diseases of bone such as cancer or infection. Our lead compound NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site. Preclinical studies demonstrate that this results in rapid increases in bone density, strength, and other severe bone diseases. Quince’s lead compound NOV004 is expected to enter Phase 1 clinical studies in 2023 and advance to a lead indication in osteogenesis imperfecta. Our pipeline also includes legacy neuroscience and antiviral programs available for out-licensing.